Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
tramadol (tramadol hydrochloride)
Losan Pharma GmbH
N02AX02
tramadol (tramadol hydrochloride)
50mg
tablets effervescent
(10) in plastic container
Prescription
Registered
2022-08-10
SPECIFICATION - DENK PHARMA product name: Tramadol Denk 50 artwork: leaflet language(s): EN, FR, PT material number: 50001166/004 storage conditions: 25°C revision of text: 07/2021 open format: 600 x 200 mm fold: 1 x pre-folded (Einbruchfalz) folded format: 300 x 200 mm pharma code: 975 paper grammar: 40 g/m 2 printing colours: PANTONE YELLOW C BLACK revision/date: 1 / 15.12.2021, KRi 2 / 21.12.2021, KRi 3 / 22.12.2021, KRi 4 / 11.01.2022, KRi _Tramadol Denk 50_ Effervescent tablet – oral use Opioid analgesic Active substance: tramadol Package leaflet: Information for the patient READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPOR- TANT INFORMATION FOR YOU. – Keep this leaflet. You may need to read it again. – If you have any further questions, ask your doc- tor or pharmacist. – This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. – If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. WHAT TRAMADOL DENK 50 IS AND WHAT IT IS USED FOR 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE TRAMADOL DENK 50 3. HOW TO TAKE TRAMADOL DENK 50 4. POSSIBLE SIDE EFFECTS 5. HOW TO STORE TRAMADOL DENK 50 6. CONTENTS OF THE PACK AND OTHER INFORMATION 1. What Tramadol Denk 50 is and what it is used for Tramadol – the active substance in Tramadol Denk 50 – is a centrally acting analgesic (painkiller) belonging to the opioid group. It achieves its pain-relieving effect by acting on specific nerve cells of the spinal cord and brain. Tramadol Denk 50 is used for the treatment of moderate to severe pain. 2. What you need to know before you take Tramadol Denk 50 Do not take Tramadol Denk 50 • if you are allergic to tramadol or any of the other ingre- dients of this medicine (listed in section 6). • in acute cases of intoxication with alcohol, sleeping tablets, p Read the complete document
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Tramadol Denk 50 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance : tramadol Each effervescent tablet contains 50 mg tramadol hydrochloride. Excipients with known effect: Each effervescent tablet contains 10 mg aspartame, 75 mg lactose monohydrate and 214 mg sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Effervescent tablet White, round, flat effervescent tablets. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Moderately severe to severe pain. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY The dosage should be adjusted to the intensity of the pain and the sensitivity of the individual patient. The lowest effective dose for analgesia should generally be selected. Unless otherwise prescribed, Tramadol Denk 50 should be dosed as follows: Adults and adolescents aged 12 years and older For moderately severe pain, 1 Tramadol Denk 50 effervescent tablet (equivalent to 50 mg tramadol hydrochloride). If no pain relief occurs within 30 - 60 minutes, a second effervescent tablet can be taken. If the demand is likely to be higher for severe pain, 2 Tramadol Denk 50 effervescent tablets (equivalent to 100 mg tramadol hydrochloride) are taken as a single dose. Depending on the pain, the effect lasts for 4 - 8 hours. It is generally not necessary to exceed daily doses of 8 effervescent tablets (equivalent to 400 mg tramadol hydrochloride). However, even much higher doses may be required for tumour pain and severe postoperative pain. More suitable pharmaceutical forms may have to be selected. _ _ _ _ 2 Children and adolescents Tramadol Denk 50 is not intended for use in children below 25 kg body weight and does not generally allow for individual dosing in children below 12 years of age. More suitable pharmaceutical forms should therefore be selected. Geriatric patients A dose adjustment is not usually necessary in patients up to 75 years without clinically manifest hepatic or renal insufficiency. In elderl Read the complete document